

# Essential criteria for pharmacokinetic studies supporting tiotropium bromide products

Clinical Pharmacology in Drug Development

5, 52-56

DOI: [10.1002/cpdd.187](https://doi.org/10.1002/cpdd.187)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of tiotropium administered by Respimat <sup>®</sup> in asthma patients: Analysis of pooled data from Phase II and III clinical trials. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 42, 25-32.	1.1	12
2	Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies. <i>Clinical Drug Investigation</i> , 2017, 37, 705-707.	1.1	2
3	Pharmacokinetics and safety of tiotropium+olodaterol 5 $\hat{1}$ / <sub>4</sub> g/5 $\hat{1}$ / <sub>4</sub> g fixed-dose combination in Chinese patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 63, 101944.	1.1	2